Literature DB >> 11697438

Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.

M Kamaluddin1, P McNally, F Breatnach, A O'Marcaigh, D Webb, E O'Dell, P Scanlon, K Butler, A O'Meara.   

Abstract

UNLABELLED: Eight consecutive paediatric patients with acute lymphoblastic leukaemia (ALL) (n = 7) and T-cell non-Hodgkin's lymphoma (NHL) (n = 1) presenting within a 5-wk interval were started on a standard induction protocol which included weekly treatment with vincristine for 4 wk. Itraconazole was commenced as antifungal prophylaxis, 1-21 d after the first injection of vincristine. Within 2 to 4 wk, enhanced vincristine neurotoxicity was noted in all patients, abdominal cramps and constipation occurred most frequently, and one patient developed a bowel perforation associated with paralytic ileus. Hyponatraemia associated with SIADH was observed in three patients and four patients developed seizures. An additional patient with B cell NHL developed seizures 5 d after an injection of vincristine. Recovery was complete in all patients and ranged from 2 d to 15 wk.
CONCLUSION: The extent and consistency of adverse effects documented in this study support the recommendation that concurrent administration of vincristine and itraconazole should be avoided.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11697438     DOI: 10.1080/080352501317061675

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  9 in total

Review 1.  Azole interactions with multidrug therapy in pediatric oncology.

Authors:  Antonio Ruggiero; Roberta Arena; Andrea Battista; Daniela Rizzo; Giorgio Attinà; Riccardo Riccardi
Journal:  Eur J Clin Pharmacol       Date:  2012-06-02       Impact factor: 2.953

Review 2.  Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.

Authors:  Brad Moriyama; Stacey A Henning; Janice Leung; Oluwaseun Falade-Nwulia; Paul Jarosinski; Scott R Penzak; Thomas J Walsh
Journal:  Mycoses       Date:  2011-11-29       Impact factor: 4.377

3.  Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants.

Authors:  Arne Simon; Mette Besuden; Sandra Vezmar; Carola Hasan; Dagmar Lampe; Sigrid Kreutzberg; Axel Glasmacher; Udo Bode; Gudrun Fleischhack
Journal:  Support Care Cancer       Date:  2006-08-30       Impact factor: 3.603

Review 4.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 5.  Drug interactions in childhood cancer.

Authors:  Cyrine Haidar; Sima Jeha
Journal:  Lancet Oncol       Date:  2010-09-22       Impact factor: 41.316

6.  The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study.

Authors:  Yoshikazu Ito; Kazuma Ohyashiki; Isao Yoshida; Makoto Takeuchi; Yasutaka Aoyama; Atsuko Mugitani; Yasuhiro Matsuura; Hisashi Wakita; Mitsuhiro Matsuda; Erina Sakamoto; Toru Kiguchi; Akio Urabe; Kazuo Tamura; Akihisa Kanamaru; Toru Masaoka
Journal:  Int J Hematol       Date:  2007-02       Impact factor: 2.490

7.  Clinical Analysis of Adverse Drug Reactions between Vincristine and Triazoles in Children with Acute Lymphoblastic Leukemia.

Authors:  Lihua Yang; Lihua Yu; Xinxin Chen; Yanqun Hu; Bin Wang
Journal:  Med Sci Monit       Date:  2015-06-07

8.  Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review.

Authors:  Marie Lindhard Madsen; Hanne Due; Niels Ejskjær; Paw Jensen; Jakob Madsen; Karen Dybkær
Journal:  Cancer Chemother Pharmacol       Date:  2019-06-18       Impact factor: 3.333

9.  Hyponatremia During Induction Therapy in Distinct Pediatric Oncological Cohorts: A Retrospective Study.

Authors:  Christina Salvador; Robert Salvador; Peter Willeit; Christine Kuntner; Alexandra Haid; Thomas Müller; Gabriele Kropshofer; Roman Crazzolara
Journal:  Front Oncol       Date:  2021-10-29       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.